Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates for oncology. Its primary pipeline includes ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist. The company has no approved products and has incurred operating losses since inception.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Revenue | $0 | $1,300 | $0 | $1,300 |
| Net Loss | $(36,650) | $(28,654) | $(70,091) | $(71,965) |
| Loss Per Share (Basic/Diluted) | $(2.34) | $(1.85) | $(4.49) | $(4.65) |
| Operating Expenses | $32,149 | $28,689 | $63,076 | $71,590 |
| Cash and Cash Equivalents (End of Period) | $133,344 | $186,567 | $133,344 | $186,567 |
| Long-Term Debt (Net) | $176,285 | $100,559 | $176,285 | $100,559 |
| Accumulated Deficit | $(316,278) | $(178,097) | $(316,278) | $(178,097) |
Liquidity: As of June 30, 2026, the company held $133.3 million in cash. Management believes this is sufficient to fund operations for at least 12 months. The company has an accumulated deficit of $316.3 million.
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the three and six months ended June 30, 2026, compared to $1.3 million in the same periods in 2025. The 2025 revenue was a one-time license fee from Scithera, Inc., which was fully recognized in Q2 2025.
- Operating Expenses:
- Q2 Comparison: Total operating expenses increased 12% to $32.1 million (from $28.7 million). Research and Development (R&D) rose 7% to $23.9 million, driven by increased contract manufacturing ($1.6M increase) and clinical trial costs ($1.2M increase). General and Administrative (G&A) expenses increased 28% to $8.3 million, primarily due to pre-commercialization activities for ozekibart.
- 6M Comparison: Total operating expenses decreased 12% to $63.1 million (from $71.6 million). R&D expenses decreased 17% to $49.1 million due to reduced clinical trial and contract manufacturing costs as certain activities for ozekibart approached completion. G&A expenses increased 12% to $14.0 million.
- Debt and Interest: Interest expense increased significantly (81% in Q2, 58% in 6M) due to the March 2026 Amendment to the 2025 Loan Agreement, which added $75.0 million in principal (Term B Loans). Total long-term debt increased from $100.6 million to $176.3 million.
- Cash Flow: Net cash used in operating activities was $67.9 million for the six months ended June 30, 2026, compared to $65.8 million in the prior year. Net cash provided by financing activities was $77.1 million, primarily from the $75.0 million debt tranche.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Ozekibart (INBRX-109):
- Chondrosarcoma: The FDA accepted the Biologics License Application (BLA) for filing in June 2026. The registrational trial met its primary endpoint, showing a 52% reduction in risk of disease progression or death compared to placebo.
- Colorectal Cancer (CRC): Interim data showed a 20% Objective Response Rate (ORR) in combination with FOLFIRI. The company plans to meet with the FDA in Q4 2026 to discuss a first-line registrational trial.
- Ewing Sarcoma: Interim data showed a 64.5% ORR. Enrollment in the Phase 1/2 trial is expected to complete in 2027.
- INBRX-106: Positive interim results were announced in May 2026 for the HexAgon study in Head and Neck Squamous Cell Carcinoma (HNSCC), showing a 44.0% ORR for the combination arm vs. 21.4% for control. The company plans to begin the Phase 3 portion of the study in Q3 2026.
- Capital Needs: The company expects to continue incurring net losses. Future funding will be sought through equity offerings, debt financings, or strategic collaborations.
Risks and Contingencies
- Regulatory Risk: While the BLA for ozekibart is under review, there is no assurance of approval. FDA Form 483 observations were issued during clinical inspections, which could delay review or result in a Complete Response Letter.
- Commercialization Risk: The company has no experience commercializing products. Success depends on building sales, marketing, and distribution capabilities.
- Liquidity Risk: If additional funding is not secured, the company may need to reduce spending, delay programs, or relinquish rights to its technology.
- Debt Covenants: The Amended 2025 Loan Agreement includes a minimum liquidity threshold covenant of $40.0 million. The company is currently in compliance.
Subsequent Events
On July 15, 2026, the company entered into a Second Amendment to the 2025 Loan Agreement, providing for up to an additional $325.0 million in gross proceeds. $100.0 million (Term C Loan) was funded upon execution, with up to $225.0 million available in future tranches.
Investor Verification Checklist
- BLA Status: Verify the current status of the FDA review for the ozekibart BLA in chondrosarcoma and any potential Complete Response Letters.
- Debt Structure: Review the terms of the July 2026 Second Amendment to the Loan Agreement, specifically the interest rates, covenants, and repayment schedule for the new $100M tranche.
- Cash Runway: Confirm the updated cash runway given the recent $100M debt drawdown and ongoing burn rate.
- Clinical Data: Monitor upcoming data readouts for INBRX-106 in HNSCC (PFS data expected Q3 2026) and ozekibart in CRC (interim results expected Q1 2027).
- Manufacturing: Assess the capacity and reliability of third-party CDMOs for commercial-scale production of ozekibart pending approval.